
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
Key Takeaways
- Approximately 1 in 9 US adults uses GLP-1 receptor agonists; prevalence may be declining, yet severe obesity continues to increase, underscoring residual unmet need and treatment stratification.
- GLP-1 RAs represent the first scalable, highly effective obesity pharmacotherapy with trial evidence for ASCVD risk reduction and CKD progression attenuation in at-risk populations.
Report urges payment reform, food policy changes, and wider treatment access, warning that drugs alone can't fix obesity's root causes.
Effective obesity management medications offer a significant opportunity to curb obesity, but no single intervention will be enough to reverse an epidemic rooted in structural and environmental drivers, according to a report from the JAMA Summit on Obesity published in
“Obesity is one of the most difficult challenges of the modern era, affecting more than 1 billion people worldwide,” wrote the authors of the study. “Nearly half of US adults and 1 in 5 US children meet the medical definition of having obesity, with major consequences for cardiometabolic, kidney, hepatic, pulmonary, musculoskeletal, reproductive, oncologic, and mental health. Obesity also carries social and economic harms through stigma, discrimination, and bias.”
The paper publishes alongside a simultaneous presentation held at ObesityWeek 2026.
JAMA convened the summit in Chicago in May 2026, bringing together patients, clinicians, scientists, economists, policy experts, and representatives from government and the food, wellness, and pharmaceutical industries.
What Percentage of US Adults Are Currently Taking GLP-1 RAs?
An estimated 1 in 9, roughly 11.11% of US adults, is currently taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA), and US obesity prevalence may be declining for the first time in decades, presumably due principally to high use of these drugs, the authors wrote. Severe obesity, however, continues to rise steadily.
The authors described GLP-1 RAs as the first scalable, highly effective medical treatments for obesity, with trials in at-risk populations showing benefits such as lower atherosclerotic cardiovascular disease risk and reduced progression to chronic kidney disease. Still, access, affordability, tolerability, and the chronicity of use remain major challenges. Strong demand, coupled with curtailed access through traditional health care, has fueled a rapidly expanding direct-to-consumer market for both FDA-approved medications and
How Should Obesity Management Be Covered by Insurance Plans?
The current health insurance system discourages obesity treatment by not covering it or by requiring onerous prior authorizations, according to the report. The authors called for coverage of lifestyle, medical, and surgical services, with priority given to populations that would benefit most, and for a shift from paying only for obesity's complications to paying for the benefits of obesity management. Given high rates of treatment discontinuation in the first year, the authors stressed framing obesity management as chronic therapy and supporting patients to persist with it.
The report also recommended building obesity care into clinician training, expanding team-based models that include dietitians and pharmacists, and establishing multidisciplinary, annual obesity treatment guidelines, as currently exist for diabetes.
The report suggested that the Medicare GLP-1 Bridge pilot and the Medicaid Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) initiative could be expanded if successful. The Bridge began July 1, 2026, offering eligible Part D beneficiaries certain GLP-1s for a $50 monthly copay and was extended through the end of 2027 after the CMS indefinitely delayed the Medicare portion of BALANCE; the Medicaid component is moving forward.2 The authors also called for stronger regulation of drug compounding, including enforcement against compounded copies of FDA-approved products outside of drug shortage conditions.1
Food Policy, Stigma, and Research Gaps
On prevention, the authors pointed to federal action on agricultural subsidies, food labeling, and marketing, including restrictions on marketing unhealthy food to children, as well as strengthened school nutrition standards and investment in food assistance programs and Medicaid. The authors also warned that forthcoming work requirements and cuts to the Supplemental Nutrition Assistance Program and Medicaid may further curtail those programs' role in obesity management.
The report also called for stigma-free care environments and for moving beyond weight loss as the primary outcome for drug approval toward measures that capture metabolic, functional, and patient-centered outcomes.
“The emergence of effective obesity management medications offers a significant opportunity to curb the prevalence of obesity,” wrote the authors. “However, no single intervention will be enough. Sustained improvement will require addressing the underlying structural and environmental drivers of obesity, along with person-centered, multilevel strategies that simultaneously improve prevention, reduce stigma, and expand equitable access to evidence-based treatment. Coordinated action across government, health care systems, clinicians, payers, industry, schools, communities, and researchers will be essential to achieving long-term improvement.”
References
- Cappola AR, Angus DC, Ahima RS, et al. Toward a healthier future through obesity prevention and care: the JAMA Summit Report on obesity. JAMA. Published online November 17, 2026. doi:10.1001/jama.2026.19759
- Freed M, Cubanski J, Williams E. What to know about the BALANCE model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. KFF. May 11, 2026. Accessed November 13, 2026.
https://www.kff.org/medicare/issue-brief/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
Related to this article







